Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07392255 · ClinicalTrials.gov registry record · Phase 1
An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)
A Phase 1 study of Geographic Atrophy Secondary to Age-related Macular Degeneration, sponsored by Complement Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
- 3
- Study locations
NCT07392255 is a Phase 1 study of Geographic Atrophy Secondary to Age-related Macular Degeneration that is actively recruiting participants, run by Complement Therapeutics. The registered enrollment target is 75 participants, below the 207-participant average among 4 other Geographic Atrophy Secondary to Age-related Macular Degeneration trials with a reported enrollment target (64% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT07392255, a Phase 1 study of Geographic Atrophy Secondary to Age-related Macular Degeneration, is actively recruiting participants, sponsored by Complement Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a clinical study to evaluate the safety, tolerability and efficacy of CTx001, administered via a single subretinal injection, for GA (secondary to AMD). Safety and efficacy will be measured at regular intervals for 2 years after which long-term safety will be assessed annually for up to 5 years.
Conditions Studied
Interventions
- GENETIC CTx001
Study Locations (3)
Indiana
- Midwest Eye Institute - Carmel
Nevada
- Sierra Eye Associates - Reno
Texas
- Retina Foundation of the Southwest - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2025-12-30 |
| Est. Completion | 2032-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07392255
The ClinicalTrials.gov registry entry for NCT07392255 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 207-participant average among 4 other Geographic Atrophy Secondary to Age-related Macular Degeneration trials with a reported enrollment target (64% lower). The listed sponsor is Complement Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Geographic Atrophy Secondary to Age-related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which CTx001 is the first listed.
NCT07392255 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Indiana, Nevada, Texas.
Frequently Asked Questions
What is clinical trial NCT07392255 about?
NCT07392255 is a clinical study titled "An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)". This is a clinical study to evaluate the safety, tolerability and efficacy of CTx001, administered via a single subretinal injection, for GA (secondary to AMD). Safety and efficacy will be measured at regular intervals for 2 years after which long-term safety will be assessed annually for up to 5 y...
What is the current status of trial NCT07392255?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2025-12-30. Estimated completion is 2032-06-30.
What conditions does trial NCT07392255 study?
This clinical trial studies the following conditions: Geographic Atrophy Secondary to Age-related Macular Degeneration.
What interventions are being tested in trial NCT07392255?
The interventions under investigation include: CTx001 (GENETIC).
Who is sponsoring clinical trial NCT07392255?
This trial is sponsored by Complement Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07392255 being conducted?
This trial has 3 study locations across Indiana, Nevada, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Geographic Atrophy Secondary to Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio
RECRUITING · Phase 2
-
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
RECRUITING · Phase 2
-
A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.